NASDAQ:SGMO - Sangamo Therapeutics Stock Price, Forecast & News

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Sangamo Therapeutics Inc (NASDAQ:SGMO) issued its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.10. The biopharmaceutical company earned $21.96 million during the quarter, compared to analysts' expectations of $12.16 million. Sangamo Therapeutics had a negative return on equity of 30.33% and a negative net margin of 159.12%. The business's revenue was down 6.8% on a year-over-year basis. During the same period last year, the business earned ($0.13) earnings per share. View Sangamo Therapeutics' Earnings History.

Sangamo Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Sangamo Therapeutics.

3 brokerages have issued 1-year target prices for Sangamo Therapeutics' shares. Their forecasts range from $11.00 to $16.00. On average, they expect Sangamo Therapeutics' share price to reach $13.50 in the next twelve months. This suggests a possible upside of 86.0% from the stock's current price. View Analyst Price Targets for Sangamo Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sangamo Therapeutics.

Media coverage about SGMO stock has been trending positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sangamo Therapeutics earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Sangamo Therapeutics.

Some companies that are related to Sangamo Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Brainstorm Cell Therapeutics (BCLI), Advanced Micro Devices (AMD), Micron Technology (MU), Novavax (NVAX), Crispr Therapeutics (CRSP), Zuora (ZUO), Alibaba Group (BABA), Gilead Sciences (GILD) and Netflix (NFLX).

Sangamo Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.60%), California Public Employees Retirement System (0.21%), Tocqueville Asset Management L.P. (0.12%), Dupont Capital Management Corp (0.04%), Alpine Global Management LLC (0.03%) and Vanguard Capital Wealth Advisors (0.03%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, H Stewart Parker, Kathy Yi, Saira Ramasastry and Steven J Mento. View Institutional Ownership Trends for Sangamo Therapeutics.

SGMO stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Sangamo Therapeutics.

SGMO stock was acquired by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., California Public Employees Retirement System, Alpine Global Management LLC, Dupont Capital Management Corp, McGuire Investment Group LLC, Patriot Financial Group Insurance Agency LLC, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA and Vanguard Capital Wealth Advisors. View Insider Buying and Selling for Sangamo Therapeutics.

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SGMO stock can currently be purchased for approximately $7.26.

Sangamo Therapeutics has a market capitalization of $841.71 million and generates $84.45 million in revenue each year. The biopharmaceutical company earns $-68,330,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 302 workers across the globe.View Additional Information About Sangamo Therapeutics.

The official website for Sangamo Therapeutics is http://www.sangamo.com/.

Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]